Skip to main content
PMC home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1999 Apr;80(4):334–338. doi: 10.1136/adc.80.4.334

Growth hormone treatment in young children with Down's syndrome: effects on growth and psychomotor development

G Anneren 1, T Tuvemo 1, C Carlsson-Skwirut 1, T Lonnerholm 1, P Bang 1, V Sara 1, J Gustafsson 1
PMCID: PMC1717881  PMID: 10086938

Abstract

BACKGROUND—Learning disability and short stature are cardinal signs of Down's syndrome. Insulin-like growth factor I (IGF-I), regulated by growth hormone (GH) from about 6 months of age, may be involved in brain development.
AIMS—To study long term effects of GH on linear growth and psychomotor development in young children with Down's syndrome. 
Study design—Fifteen children with Down's syndrome were treated with GH for three years from the age of 6 to 9 months (mean, 7.4). Linear growth, psychomotor development, skeletal maturation, serum concentrations of IGF-I and its binding proteins (BPs), and cerebrospinal fluid (CSF) concentrations of IGF-II were studied.
RESULTS—The mean height of the study group increased from −1.8 to −0.8 SDS (Swedish standard) during treatment, whereas that of a Down's syndrome control group fell from −1.7 to −2.2 SDS. Growth velocity declined after treatment stopped. Head growth did not accelerate during treatment. No significant difference in mental or gross motor development was found. The low concentrations of serum IGF-I and IGFBP-3 became normal during GH treatment.
CONCLUSIONS—GH treatment results in normal growth velocity in Down's syndrome but does not affect head circumference or mental or gross motor development. Growth velocity declines after treatment stops.



Full Text

The Full Text of this article is available as a PDF (117.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adem A., Jossan S. S., d'Argy R., Gillberg P. G., Nordberg A., Winblad B., Sara V. Insulin-like growth factor 1 (IGF-1) receptors in the human brain: quantitative autoradiographic localization. Brain Res. 1989 Dec 4;503(2):299–303. doi: 10.1016/0006-8993(89)91678-8. [DOI] [PubMed] [Google Scholar]
  2. Allen D. B., Frasier S. D., Foley T. P., Jr, Pescovitz O. H. Growth hormone for children with Down syndrome. J Pediatr. 1993 Nov;123(5):742–743. doi: 10.1016/s0022-3476(05)80849-2. [DOI] [PubMed] [Google Scholar]
  3. Annerén G., Enberg G., Sara V. R. The presence of normal levels of serum immunoreactive insulin-like growth factor 2 (IGF-2) in patients with Down's syndrome. Ups J Med Sci. 1984;89(3):274–278. doi: 10.3109/03009738409179508. [DOI] [PubMed] [Google Scholar]
  4. Annerén G., Sara V. R., Hall K., Tuvemo T. Growth and somatomedin responses to growth hormone in Down's syndrome. Arch Dis Child. 1986 Jan;61(1):48–52. doi: 10.1136/adc.61.1.48. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bang P., Eriksson U., Sara V., Wivall I. L., Hall K. Comparison of acid ethanol extraction and acid gel filtration prior to IGF-I and IGF-II radioimmunoassays: improvement of determinations in acid ethanol extracts by the use of truncated IGF-I as radioligand. Acta Endocrinol (Copenh) 1991 Jun;124(6):620–629. doi: 10.1530/acta.0.1240620. [DOI] [PubMed] [Google Scholar]
  6. Brismar K., Fernqvist-Forbes E., Wahren J., Hall K. Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes. J Clin Endocrinol Metab. 1994 Sep;79(3):872–878. doi: 10.1210/jcem.79.3.7521354. [DOI] [PubMed] [Google Scholar]
  7. Carr J. Six weeks to twenty-one years old: a longitudinal study of children with Down's syndrome and their families. Third Jack Tizard memorial lecture. J Child Psychol Psychiatry. 1988 Jul;29(4):407–431. doi: 10.1111/j.1469-7610.1988.tb00734.x. [DOI] [PubMed] [Google Scholar]
  8. Castells S., Beaulieu I., Torrado C., Wisniewski K. E., Zarny S., Gelato M. C. Hypothalamic versus pituitary dysfunction in Down's syndrome as cause of growth retardation. J Intellect Disabil Res. 1996 Dec;40(Pt 6):509–517. doi: 10.1046/j.1365-2788.1996.802802.x. [DOI] [PubMed] [Google Scholar]
  9. Cronk C., Crocker A. C., Pueschel S. M., Shea A. M., Zackai E., Pickens G., Reed R. B. Growth charts for children with Down syndrome: 1 month to 18 years of age. Pediatrics. 1988 Jan;81(1):102–110. [PubMed] [Google Scholar]
  10. Gargosky S. E., Pham H. M., Wilson K. F., Liu F., Giudice L. C., Rosenfeld R. G. Measurement and characterization of insulin-like growth factor binding protein-3 in human biological fluids: discrepancies between radioimmunoassay and ligand blotting. Endocrinology. 1992 Dec;131(6):3051–3060. doi: 10.1210/endo.131.6.1280211. [DOI] [PubMed] [Google Scholar]
  11. Gluckman P., Klempt N., Guan J., Mallard C., Sirimanne E., Dragunow M., Klempt M., Singh K., Williams C., Nikolics K. A role for IGF-1 in the rescue of CNS neurons following hypoxic-ischemic injury. Biochem Biophys Res Commun. 1992 Jan 31;182(2):593–599. doi: 10.1016/0006-291x(92)91774-k. [DOI] [PubMed] [Google Scholar]
  12. Juul A., Bang P., Hertel N. T., Main K., Dalgaard P., Jørgensen K., Müller J., Hall K., Skakkebaek N. E. Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab. 1994 Mar;78(3):744–752. doi: 10.1210/jcem.78.3.8126152. [DOI] [PubMed] [Google Scholar]
  13. Karlberg P., Taranger J., Engström I., Karlberg J., Landström T., Lichtenstein H., Lindstrom B., Svennberg-Redegren I. I. physical growth from birth to 16 years and longitudinal outcome of the study during the same age period. Acta Paediatr Scand Suppl. 1976;(258):7–76. doi: 10.1111/j.1651-2227.1976.tb14761.x. [DOI] [PubMed] [Google Scholar]
  14. Lobie P. E., García-Aragón J., Lincoln D. T., Barnard R., Wilcox J. N., Waters M. J. Localization and ontogeny of growth hormone receptor gene expression in the central nervous system. Brain Res Dev Brain Res. 1993 Aug 20;74(2):225–233. doi: 10.1016/0165-3806(93)90008-x. [DOI] [PubMed] [Google Scholar]
  15. McGauley G. A. Quality of life assessment before and after growth hormone treatment in adults with growth hormone deficiency. Acta Paediatr Scand Suppl. 1989;356:70–74. doi: 10.1111/j.1651-2227.1989.tb11249.x. [DOI] [PubMed] [Google Scholar]
  16. Milunsky A., Lowy C., Rubenstein A. H., Wright A. D. Carbohydrate tolerance, growth hormone and insulin levels in mongolism. Dev Med Child Neurol. 1968 Feb;10(1):25–31. doi: 10.1111/j.1469-8749.1968.tb02833.x. [DOI] [PubMed] [Google Scholar]
  17. POZSONYI J., GIBSON D., ZARFAS D. E. SKELETAL MATURATION IN MONGOLISM (DOWN'S SYNDROME). J Pediatr. 1964 Jan;64:75–78. doi: 10.1016/s0022-3476(64)80319-x. [DOI] [PubMed] [Google Scholar]
  18. Påhlman S., Meyerson G., Lindgren E., Schalling M., Johansson I. Insulin-like growth factor I shifts from promoting cell division to potentiating maturation during neuronal differentiation. Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):9994–9998. doi: 10.1073/pnas.88.22.9994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Póvoa G., Roovete A., Hall K. Cross-reaction of serum somatomedin-binding protein in a radioimmunoassay developed for somatomedin-binding protein isolated from human amniotic fluid. Acta Endocrinol (Copenh) 1984 Dec;107(4):563–570. doi: 10.1530/acta.0.1070563. [DOI] [PubMed] [Google Scholar]
  20. Ruvalcaba R. H., Thuline H. C., Kelley V. C. Plasma growth hormone in patients with chromosomal anomalies. Arch Dis Child. 1972 Apr;47(252):307–309. doi: 10.1136/adc.47.252.307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Sara V. R., Gustavson K. H., Annerén G., Hall K., Wetterberg L. Somatomedins in Down's syndrome. Biol Psychiatry. 1983 Jul;18(7):803–811. [PubMed] [Google Scholar]
  22. Sara V. R., Sjögren B., Annerén G., Gustavson K. H., Forsman A., Hall K., Wahlström J., Wetterberg L. The presence of normal receptors for somatomedin and insulin in fetuses with Down's syndrome. Biol Psychiatry. 1984 Apr;19(4):591–598. [PubMed] [Google Scholar]
  23. Tham A., Nordberg A., Grissom F. E., Carlsson-Skwirut C., Viitanen M., Sara V. R. Insulin-like growth factors and insulin-like growth factor binding proteins in cerebrospinal fluid and serum of patients with dementia of the Alzheimer type. J Neural Transm Park Dis Dement Sect. 1993;5(3):165–176. doi: 10.1007/BF02257671. [DOI] [PubMed] [Google Scholar]
  24. Torrado C., Bastian W., Wisniewski K. E., Castells S. Treatment of children with Down syndrome and growth retardation with recombinant human growth hormone. J Pediatr. 1991 Sep;119(3):478–483. doi: 10.1016/s0022-3476(05)82068-2. [DOI] [PubMed] [Google Scholar]
  25. Zapf J., Walter H., Froesch E. R. Radioimmunological determination of insulinlike growth factors I and II in normal subjects and in patients with growth disorders and extrapancreatic tumor hypoglycemia. J Clin Invest. 1981 Nov;68(5):1321–1330. doi: 10.1172/JCI110379. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES